Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision Biosciences Inc (NQ: DTIL )

1.160 -0.030 (-2.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 379,316
Open 1.200
Bid (Size) 1.160 (7)
Ask (Size) 1.350 (1)
Prev. Close 1.190
Today's Range 1.150 - 1.200
52wk Range 0.9500 - 5.200
Shares Outstanding 110,958,955
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones
From Precision BioSciences
Via Business Wire
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
From Precision BioSciences, Inc.
Via Business Wire

Performance

YTD
-0.85%
-0.85%
1 Month
+16.81%
+16.81%
3 Month
-16.55%
-16.55%
6 Month
-23.68%
-23.68%
1 Year
-74.34%
-74.34%

More News

Read More
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Earnings Perspective: Return On Capital Employed
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Precision BioSciences Announces Change to its Board of Directors
From Precision BioSciences, Inc.
Via Business Wire
Coinbase To $80? Plus Deutsche Bank Cuts PT On This Stock By 80%
Via Benzinga
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences's Earnings Outlook
Via Benzinga
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Senior Leadership Organizational Changes
From Precision BioSciences, Inc.
Via Business Wire
Looking Into Precision BioSciences, Inc. - Common Stock's Return On Capital Employed
Via Benzinga
Precision BioSciences: Q2 Earnings Insights
Via Benzinga
Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Earnings Preview: Precision BioSciences, Inc. - Common Stock
Via Benzinga
Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.